SAN FRANCISCO, CA--(Marketwire - December 28, 2009) - Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS) today announced that it has received notification from The NASDAQ Stock Market that it has regained compliance with the minimum $1.00 per share bid price requirement. As required under NASDAQ’s Listing Rules, to regain compliance, the Company was required to evidence a closing bid price of $1.00 per share or more for at least ten consecutive days. On December 23, 2009, the closing bid price of the Company’s common stock was $1.34 per share, the tenth consecutive day the stock price had closed above $1.00 per share.
About Sunesis Pharmaceuticals
Sunesis is a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. Sunesis has built a highly experienced cancer drug development organization committed to advancing its lead product candidate, voreloxin, in multiple indications to improve the lives of people with cancer. For additional information on Sunesis Pharmaceuticals, please visit http://www.sunesis.com.
SUNESIS and the logo are trademarks of Sunesis Pharmaceuticals, Inc.
Investor and Media Inquiries:
David Pitts
Argot Partners
212-600-1902
Eric Bjerkholt
Sunesis Pharmaceuticals Inc.
650-266-3717
